Amryt Pharma

16 articles with Amryt Pharma

• Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings

  6/28/2021

  The Company’s annual report for the 12 months ended 31 December 2020, will be posted to shareholders in the coming days, along with a notice of general meeting.

• Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.

  6/15/2021

  Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.

• FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting

  6/7/2021

  DUBLIN, Ireland, and Boston MA, June 7, 2021, Amryt, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that the U.S. Food and Drug Administration has confirmed that Amryt’s New Drug Application for Oleogel-S10 for the treatment of Epidermolysis Bullosa will not require an Advisory Committee meeting.

• FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

  6/3/2021

  Amryt, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that the U.S. Food and Drug Administration has granted Priority Review for Amryt’s New Drug Application for Oleogel-S10 for the treatment of Epidermolysis Bullosa.

• Amryt Reports Record Q1 2021 Financial and Operating Results

  5/5/2021

  DUBLIN, Ireland, and Boston MA, May 5, 2021, Amryt, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, provides a business update and announces unaudited financial results for the first quarter ended March 31, 2021.

• 

  Amryt and Chiasma Combine to Form Rare and Orphan Diseases Powerhouse

  5/5/2021

  Amryt inked an all-stock acquisition deal with Chiasma. The combined company will focus on rare and orphan diseases with three marketed products and a strong development pipeline.
• 

  Clinical Catch-Up: September 7-11

  9/14/2020

  It was a busy week for clinical trial updates. Here’s a look.
• 

  Amryt Eyes Approval for Epidermolysis Bullosa Drug Following Phase III Data

  9/9/2020

  This morning, Dublin-based Amryt said the primary endpoint of the late-stage study was met.
• 

  A Look at the Top 20 Most Expensive Drugs in the U.S.

  2/14/2020

  These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.

• Amryt Pharma PLC: Notice of Trading Update

  11/4/2019

  Amryt, a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases, will announce a trading update for the nine-months ended 30 September 2019 on Tuesday, 5 November 2019.

• Amryt Pharma: Interim results for the six months ended 30 June 2019

  9/30/2019

  Amryt, a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases, announces interim results for the six months ended 30 June 2019.

• Amryt Pharma plc (“Amryt” or the “Company”) Update on AP101 EASE Phase III trial

  2/28/2019

  IDMC recommends study can enrol children and infants aged from 21 days to 4 years

• Amryt Pharma plc: Update on AP101 EASE Phase III trial

  2/28/2019

  Amryt, a revenue generating orphan drug company focused on acquiring, developing & commercialising products that help to improve the lives of patients where there is a high unmet medical need, today announces an update on its pivotal Phase III EASE trial for AP101 as a potential treatment for Epidermolysis Bullosa (“EB”).

• Lojuxta to be reimbursed in France

  10/18/2018

  Amryt’s lead commercial product now available in all five of the EU’s largest markets

• Amryt receives IND approval from FDA for AP101 enabling the opening of US clinical trial sites

  9/11/2018

  Amry today announces that the US Food and Drug Administration (“FDA”) has granted Investigational New Drug (“IND”) clearance for AP101.

• Treatment Of Rare Skin Disorder By Amryt Pharma Gets EUR 20 Million Backing From European Investment Bank’s First Ever Pharma Loan In Ireland

  12/2/2016